Page 46 - Read Online
P. 46
Page 10 of 14 Borek et al. Rare Dis Orphan Drugs J 2023;2:5 https://dx.doi.org/10.20517/rdodj.2022.20
3. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol
2011;8:443-55. DOI PubMed PMC
4. Hoffmann J, Wilhelm J, Marsh LM, et al. Distinct differences in gene expression patterns in pulmonary arteries of patients with
chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Am J Respir Crit Care Med
2014;190:98-111. DOI PubMed
5. Tuder RM. Pulmonary vascular remodeling in pulmonary hypertensio. Cell Tissue Res 2017;367:643-9. DOI
6. Hoffmann J, Marsh LM, Pieper M, et al. Compartment-specific expression of collagens and their processing enzymes in
intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol 2015;308:L1002-13. DOI PubMed PMC
7. Aiello VD, Gutierrez PS, Chaves MJ, Lopes AA, Higuchi ML, Ramires JA. Morphology of the internal elastic lamina in arteries from
pulmonary hypertensive patients: a confocal laser microscopy study. Mod Pathol 2003;16:411-6. DOI PubMed
8. Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the
pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011;89:771-83. DOI PubMed
9. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med
2012;186:261-72. DOI PubMed PMC
10. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir
Crit Care Med 2012;185:311-21. DOI PubMed
11. Li C, Liu P, Song R, Zhang Y, Lei S, Wu S. Immune cells and autoantibodies in pulmonary arterial hypertension. Acta Biochim
Biophys Sin (Shanghai) 2017;49:1047-57. DOI PubMed
12. Becker MO, Kill A, Kutsche M, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic
sclerosis. Am J Respir Crit Care Med 2014;190:808-17. DOI PubMed
13. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial
pulmonary arterial hypertension. Circulation 2010;122:920-7. DOI PubMed
14. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic
thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001;164:319-24. DOI PubMed
15. Dorfmüller P, Zarka V, Durand-gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit
Care Med 2002;165:5534-9. DOI PubMed
16. Balabanian K, Foussat A, Dorfmüller P, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit
Care Med 2002;165:1419-25. DOI PubMed
17. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013;144:1346-56. DOI PubMed
PMC
18. Tselios K, Gladman DD, Urowitz MB. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and
management strategies. Open Access Rheumatol 2017;9:1-9. DOI PubMed PMC
19. Duong H, Bonham CA. Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment. Clin Pulm Med
2018;25:52-60. DOI PubMed PMC
20. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-85. DOI PubMed
21. Tamosiuniene R, Tian W, Dhillon G, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.
Circ Res 2011;109:867-79. DOI PubMed PMC
22. Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med
2008;205:361-72. DOI PubMed PMC
23. Crnkovic S, Valzano F, Fließer E, et al. Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in
pulmonary artery remodeling. JCI Insight 2022:7. DOI PubMed PMC
24. Kurakula K, Smolders VFED, Tura-Ceide O, Jukema JW, Quax PHA, Goumans MJ. Endothelial dysfunction in pulmonary
hypertension: cause or consequence? Biomedicines 2021;9:57. DOI PubMed PMC
25. Le Hiress M, Tu L, Ricard N, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. role of
the macrophage migration inhibitory Factor/CD74 complex. Am J Respir Crit Care Med 2015;192:983-97. DOI PubMed
26. Marsh LM, Jandl K, Grünig G, et al. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial
hypertension. Eur Respir J 2018;51:1701214. DOI PubMed PMC
27. Heath D, Trueman T, Sukonthamarn P. Pulmonary mast cells in mitral stenosis. Cardiovasc Res 1969;3:467-71. DOI PubMed
28. Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J
2011;37:1400-10. DOI PubMed
29. Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir
Res 2011;12:60. DOI PubMed PMC
30. Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial
hypertension. Am J Respir Crit Care Med 2011;184:116-23. DOI PubMed
31. Kwapiszewska G, Markart P, Dahal BK, et al. PAR-2 inhibition reverses experimental pulmonary hypertension. Circ Res
2012;110:1179-91. DOI PubMed
32. Ormiston ML, Chang C, Long LL, et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary
arterial hypertension. Circulation 2012;126:1099-109. DOI PubMed
33. Rätsep MT, Moore SD, Jafri S, et al. Spontaneous pulmonary hypertension in genetic mouse models of natural killer cell deficiency.